Frazier Life Sciences IX, L.P.

Frazier Life Sciences IX, L.P. discloses dealings in 4 companies, chiefly Passage BIO, Inc., Phathom Pharmaceuticals, Inc. and Tarsus Pharmaceuticals, Inc. The record holds 12 filings, for trades running from 22 July 2019 to 20 October 2020.

The open-market record is one-sided, with 4 purchases worth €37.2M and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2020: 2 purchases and no sales on the market.

In size, the median ticket on the buying side is €7.5M. On 4 out of 4 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +62.8%. Past outcomes like these are no guarantee of what comes next.

The record was last updated on 20 October 2020 with an open-market purchase (€4.2M) in Tarsus Pharmaceuticals, Inc. Most trades are made public on the day they happen. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.